{
    "clinical_study": {
        "@rank": "316",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 07, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04325672"
        },
        "id_info": {
            "org_study_id": "20-002864",
            "nct_id": "NCT04325672"
        },
        "brief_title": "Convalescent Plasma to Limit Coronavirus Associated Complications",
        "official_title": "Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic",
                "agency_class": "Other"
            }
        },
        "source": "Mayo Clinic",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Researchers are trying to assess the treatment potential and safety of anti-SARS-CoV-2\n      convalescent plasma in patients with acute respiratory symptoms with confirmed COVID-19."
        },
        "detailed_description": {
            "textblock": "High titer human convalescent plasma will be extracted from apheresis donations from twenty\n      recently-sick and currently-recovered COVID-19 patients. An open-label, phase 2A clinical\n      trial will then be conducted to administer convalescent plasma to twenty individuals with\n      confirmed cases of COVID-19 to investigate the novel application of convalescent plasma in\n      the treatment strategy of SARS-CoV-2."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 1, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "December 31, 2022"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "December 31, 2022"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "intervention_model": "Single Group Assignment",
            "primary_purpose": "Basic Science",
            "masking": "None (Open Label)"
        },
        "primary_outcome": [
            {
                "measure": "RNA in SARS-CoV-2",
                "time_frame": "Days 0, 1, 3, 7, 14, 28, 60 and 90 after transfusion",
                "description": "Change in RNA levels of SARS-CoV-2 from nasopharyngeal using RT-PCR (reverse transcriptase polymerase chain reaction) across time."
            },
            {
                "measure": "ICU Admissions",
                "time_frame": "90 days after transfusion",
                "description": "Total number of subjects to be admitted to the ICU after the anti-SARS-CoV-2 convalescent plasma transfusion."
            },
            {
                "measure": "Hospital Mortality",
                "time_frame": "90 days after transfusion",
                "description": "Total number of subject deaths."
            },
            {
                "measure": "Hospital Length of Stay (LOS)",
                "time_frame": "90 days after transfusion",
                "description": "The total number of days subjects were admitted to the hospital."
            }
        ],
        "secondary_outcome": [
            {
                "measure": "Type of respiratory support",
                "time_frame": "90 days after transfusion or until hospital discharge (whichever comes first)",
                "description": "The type of supplemental oxygen support (e.g. nasal cannula, high flow nasal cannula, noninvasive ventilation, intubation and invasive mechanical ventilation, rescue ventilation) of the anti-SARS-CoV-2 convalescent plasma group across time."
            },
            {
                "measure": "Duration of respiratory support",
                "time_frame": "90 days after transfusion or until hospital discharge (whichever comes first)",
                "description": "The total number of days subjects required respiratory support."
            }
        ],
        "number_of_arms": "1",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "20"
        },
        "condition": "Coronavirus",
        "arm_group": {
            "arm_group_label": "Convalescent Plasma Group",
            "arm_group_type": "Experimental",
            "description": "Subjects will receive 1-2 units (300-600 mL) of plasma with an anti-SARS-CoV-2 titer of >1:64."
        },
        "intervention": {
            "intervention_type": "Biological",
            "intervention_name": "Convalescent Plasma",
            "description": "Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers >1:64.",
            "arm_group_label": "Convalescent Plasma Group"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must be 18 years of age or older\n\n          -  Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19\n             SARS-CoV-2 RT-PCR testing. Patient is willing and able to provide written informed\n             consent and comply with all protocol requirements.\n\n          -  Patient agrees to storage of specimens for future testing.\n\n        Exclusion Criteria:\n\n          -  Female subjects with positive pregnancy test, breastfeeding, or planning to become\n             pregnant/breastfeed during the study period\n\n          -  Receipt of pooled immunoglobulin in past 30 days\n\n          -  Contraindication to transfusion or history of prior reactions to transfusion blood\n             products"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Michael Joyner, MD",
            "role": "Principal Investigator",
            "affiliation": "Mayo Clinic"
        },
        "overall_contact": {
            "last_name": "Shelly Roberts, RN",
            "phone": "507-255-2807",
            "email": "roberts.shelly@mayo.edu"
        },
        "location": {
            "facility": {
                "name": "Mayo Clinic in Rochester",
                "address": {
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States"
                }
            }
        },
        "location_countries": {
            "country": "United States"
        },
        "link": {
            "url": "https://www.mayo.edu/research/clinical-trials",
            "description": "Mayo Clinic Clinical Trials"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "March 26, 2020",
        "study_first_submitted_qc": "March 26, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "March 27, 2020"
        },
        "last_update_submitted": "March 26, 2020",
        "last_update_submitted_qc": "March 26, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "March 27, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Principal Investigator",
            "investigator_affiliation": "Mayo Clinic",
            "investigator_full_name": "Michael J. Joyner, M.D.",
            "investigator_title": "Principal Investigator"
        },
        "keyword": [
            "2019 novel Coronavirus",
            "SARS-CoV-2",
            "COVID-19"
        ],
        "condition_browse": {
            "mesh_term": "Coronavirus Infections"
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}